Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

eing developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of Optimer's NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.  

Forward Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to the potential regulatory approval and commercialization of DIFICID, the expected timing of the FDA's review of the NDA for DIFICID, future activities conducted under the co-promotion agreement, the potential benefits of the co-promotion agreement, including benefits to the commercial launch of DIFICID, the number of hospitals to which DIFICID will be marketed, and the possibility of capturing a portion of the undiagnosed CDI market, Optimer's plans to build its own sales force, potential payments under the co-promotion agreement, and expected trends in the incidence of CDI. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer or Cubist that any of their respective plans will be achieved. Actual results may differ materially from those set forth in this release due to the implementation and continuation of the co-promotion agreement, each party's performance of its respective obligations under the co-promotion agreement, Optimer's and Cubist's ability
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... ENDO 2013, the Endocrine Society,s 95 th ... both melatonin and cortisol rhythms. This effect further ... clock and address the circadian desynchrony which is ... and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study ...
(Date:6/17/2013)... 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... has filed a preliminary prospectus supplement to its effective shelf ... similar filing with securities regulatory authorities in each of the ... a public offering of its common shares to raise gross ... Company will also grant to the underwriters of the Offering ...
(Date:6/17/2013)... June 17, 2013 The following is a Statement ... at Drugfree.org :   Last Friday, ... was halting the sale of prescription drug paraphernalia products. The ... that from time to time there may be individual items ... As a result of this misinterpretation we are electing to ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2
... it has been selected as a Finalist ... list honoring the year,s most promising private technology ventures ... The Red Herring editorial team selected the most innovative ... America. The nominees are evaluated on both quantitative and ...
... a full-service pharmacy benefit management and ancillary medical ... Craig Rollins has joined the organization as Vice ... role he will be responsible for the strategic ... 1Click Ancillary online marketplace. myMatrixx launched 1Click Ancillary ...
Cached Medicine Technology:DICOM Grid Selected as a Finalist for the 2012 Red Herring Top 100 Americas Award 2myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development 2
(Date:6/17/2013)... NY (PRWEB) June 17, 2013 The Woodstock ... Blake to attend the Festival this summer, which will be ... through Sunday, August 25th. , Blake professes the benefits ... a day to fuel his world class sprinting abilities. ... volume of fruit is drawing attention. "Yohan Blake believes in ...
(Date:6/17/2013)... City Beach, FL (PRWEB) June 17, 2013 ... higher purpose--fighting hunger. Oceana Naturals LLC, the US distributor ... region of The Bay Area Food Bank ... families, and struggling seniors by seeing that they receive ... Natural Sunscreen and All Natural Moisturizer. Contributions will ...
(Date:6/17/2013)... (June 17, 2013) A team from the New ... Naomi Berrie Diabetes Center of Columbia University has generated ... the features of maturity-onset diabetes of the young (MODY). ... patients to produce induced pluripotent stem (iPS) cells, from ... mouse, the stem cell-derived beta cells secreted insulin in ...
(Date:6/17/2013)... Keller, TX (PRWEB) June 17, 2013 Tarrant ... special. , The term ‘mommy makeover’ has recently undergone ... from surgeon to surgeon. At Tarrant Plastic Surgery, they regard ... procedures designed to remove and reverse many of the effects ... the breast may typically include: drooping of the breast with ...
(Date:6/17/2013)... new drug called pyrvinium pamoate inhibits aggressive forms of ... to a study conducted in an animal model. The ... 95th Annual Meeting in San Francisco. , "Our novel ... action," said study lead author Jeremy Jones, PhD, assistant ... Research Institute, in Duarte, CA. "Thus, it has the ...
Breaking Medicine News(10 mins):Health News:Yohan Blake Invited to The Woodstock Fruit Festival as Guest of Honor 2Health News:All Natural Sunscreen Fights Hunger 2Health News:NYSCF and Columbia researchers demonstrate use of stem cells to analyze causes, treatment of diabetes 2Health News:NYSCF and Columbia researchers demonstrate use of stem cells to analyze causes, treatment of diabetes 3Health News:Tarrant Plastic Surgery Announces Summer Makeover Special 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2
... Delhi is planning to interlink its major 29 hospitals ... and treatment provided. This computerization and interlinking of data ... by which doctors can know the case history and ... modules of software to deal with different hospital departments. ...
... number of psychiatric disorders, including mood disorders, schizophrenia// ... shown to increase the risk for emergence of ... disorder), and that presence of certain anxiety disorders ... development of nicotine dependence. ,A recent study ...
... or growing fast: systematic review of size and growth ... who grow rapidly during the first two years of life, ... a study reveals. ,There is an urgent need to ... is not clear how early in life prevention could begin. ...
... is no link whatsoever between breast cancer and cholesterol levels ... control the same. ,The details of the study ... Internal Medicine, one of the JAMA/Archives journals. The article says ... to suggest that the statins may work in conjunction with ...
... compulsory licensing (CL) provision in the Patents Act that ... Swiss drug maker Roche’s patented drug Tamiflu, useful in ... flu virus. , ,Section 92 empowers the government ... the industry. Furthermore, the issue of such license is ...
... a large, heterogeneous group of rare pulmonary disorders ... abnormal gas exchange with considerable mortality and morbidity. ... diagnosis includes more than 100 conditions in both ... and Colorado conducted a descriptive, observational study was ...
Cached Medicine News:Health News:Delhi Government To Interlink All Major Hospitals Through e-Governance 2Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2Health News:A New Diagnostic Approach To Pediatric Interstitial Lung Disease 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm straight. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: